BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alzheimer's Disease Psychosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Alzheimer's Disease P
 sychosis\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06887192-707@assetmemo.bio
DTSTAMP:20261121T010002Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Betovumeline/fesoterodine (ML-007C-MA): Phase 2 readout est. (NCT06
 887192)
DESCRIPTION:Betovumeline/fesoterodine (ML-007C-MA)\, phase 2\, Alzheimer's 
 Disease.\nStudy: A Study to Assess the Efficacy and Safety of ML-007C-MA f
 or the Treatment of Alzheimer's Disease Psychosis\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /betovumeline-fesoterodine-ml-007c-ma#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06887192
URL:https://assetmemo.bio/drug/betovumeline-fesoterodine-ml-007c-ma#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06159673-702@assetmemo.bio
DTSTAMP:20261121T010002Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Remlifanserin: Phase 2/3 readout est. (NCT06159673)
DESCRIPTION:Remlifanserin\, phase 2/3\, Alzheimer's Disease.\nStudy: ACP-20
 4 in Adults With Alzheimer's Disease Psychosis\nEstimated primary completi
 on: January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rem
 lifanserin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06159673
URL:https://assetmemo.bio/drug/remlifanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459660-707@assetmemo.bio
DTSTAMP:20261121T010002Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Betovumeline/fesoterodine (ML-007C-MA): Phase 2 readout est. (NCT07
 459660)
DESCRIPTION:Betovumeline/fesoterodine (ML-007C-MA)\, phase 2\, Alzheimer's 
 Disease.\nStudy: An Open-Label Study of ML-007C-MA in Adults With Alzheime
 r's Disease Psychosis\nEstimated primary completion: March 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/betovumeline-fesoterodine-ml-0
 07c-ma#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07459660
URL:https://assetmemo.bio/drug/betovumeline-fesoterodine-ml-007c-ma#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06194799-702@assetmemo.bio
DTSTAMP:20261121T010002Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Remlifanserin: Phase 3 readout est. (NCT06194799)
DESCRIPTION:Remlifanserin\, phase 3\, Alzheimer's Disease.\nStudy: ACP-204 
 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study\nE
 stimated primary completion: April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/remlifanserin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06194799
URL:https://assetmemo.bio/drug/remlifanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
